<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04785924</url>
  </required_header>
  <id_info>
    <org_study_id>MISP 59805</org_study_id>
    <nct_id>NCT04785924</nct_id>
  </id_info>
  <brief_title>Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections</brief_title>
  <official_title>A Study Comparing Prospective Use of Imipenem/Cilastatin/Relebactam (IMI/REL) to Retrospective Data Using Meropenem/ Vabobactam (MVB) and Ceftazidime/Avibactam (CZA) in Treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atrium Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Atrium Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observation study comparing prospective use of Imipenem/Cilastatin/Relebactam&#xD;
      (IMI/REL) to retrospective data using Meropenem/Vabobactam (MVB)and Ceftazidime/Avibactam&#xD;
      CZA) in treatment of Klebsiella Producing Carbapenemase Enterobacteriaceae infections at a&#xD;
      tertiary care hospital. The objectives of the study are to demonstrate successful treatment&#xD;
      of KPC containing Enterobacteriaceae infections with IMI/REL including in bacteremia, and to&#xD;
      analyze treatment outcomes in use of IMI/REL for KPC-producing infections compared to&#xD;
      historical clinical outcome data with CZA and MVB use at the same institution.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A study of outcomes with use of an antibiotic, IMI/REL which can be compared with retrospective data of CRE-containing infections treated with MVB and CZA.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical success</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical success defined as survival at 30 days, resolution of signs and symptoms of infection, sterilization of blood cultures within 7 days of treatment initiation in patients with bacteremia, and absence of recurrent infections.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical success by site of infection</measure>
    <time_frame>30 days</time_frame>
    <description>Clinical success in patients grouped by site of infection: bacteremia, respiratory, intra-abdominal infection, soft tissue, catheter associated and urinary tract. Subjects may be included in multiple groups if applicable for analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>Survival at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90 day Mortality</measure>
    <time_frame>90 days</time_frame>
    <description>Survival at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>90 days</time_frame>
    <description>Incidence of nephrotoxicity, leukopenia, rash, hepatotoxicity, and seizure in treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Length of hospital stays</measure>
    <time_frame>90 days</time_frame>
    <description>Days of hospitalization for CRE infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of infection</measure>
    <time_frame>90 days</time_frame>
    <description>Recurrence of CRE-containing infection within 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of resistance</measure>
    <time_frame>90 days</time_frame>
    <description>If recurrent CRE infection develops following index infection treated with IMI/REL, then incidence of IMI/REL resistance in subsequent bacterial cultures</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Carbapenem-Resistant Enterobacteriaceae Infection</condition>
  <condition>KPC</condition>
  <condition>Gram-Negative Bacterial Infections</condition>
  <condition>Antibiotic Resistant Infection</condition>
  <arm_group>
    <arm_group_label>Observation Treatment Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients observed while treated with IMI/REL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem+Relebactam</intervention_name>
    <description>Antibiotic treatment for KPC producing CRE-containing gram-negative infections</description>
    <arm_group_label>Observation Treatment Group</arm_group_label>
    <other_name>Recarbrio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (&gt;18 years of age) patients with a KPC-producing CRE infection at any site&#xD;
             except for isolated urinary source. Patients may be initially enrolled once identified&#xD;
             with a CRE infection defined as resistance to any carbapenem. Any carbapenem&#xD;
             resistance will provide an initial mechanism of identifying study eligible patients in&#xD;
             accordance with our institutions definition of CRE for infection prevention purposes.&#xD;
             As this study is specific for KPC-producing CRE inclusion in the study analysis will&#xD;
             require confirmation of a KPC gene by molecular analysis of the isolate and subjects&#xD;
             enrolled may be subsequently removed from study and excluded from analysis if&#xD;
             molecular testing reveals their CRE isolate to be a non-KPC mechanism of resistance.&#xD;
             Polymicrobial infections at same or different sites can also be included as long as&#xD;
             additional gram-negative active agents aside from IMI/REL are not needed for&#xD;
             treatment.&#xD;
&#xD;
          2. Bacterial infection with Enterobacteriaceae excluding Morganellaceae&#xD;
&#xD;
          3. Ability and willingness to give informed consent. A Legal authorized representative&#xD;
             may be used when the patient is unable to provide informed consent.&#xD;
&#xD;
          4. Be the first episode of a CRE infection to be treated with IMI/REL. Previously&#xD;
             treatment with IMI/REL for a KPC-containing Enterobacteriaceae infection will exclude&#xD;
             patients from enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receipt of more than 48 hours of effective antibiotic therapy against KPC containing&#xD;
             infections (e.g. MVB, CZA) prior to first dose of IMI/REL being administered.&#xD;
&#xD;
          2. Infections localized to urinary source alone (bloodstream infections from urinary&#xD;
             source will be included)&#xD;
&#xD;
          3. Infection with Morganellaceae&#xD;
&#xD;
          4. Prior serious allergic reaction to carbapenem therapy&#xD;
&#xD;
          5. Need for ongoing concomitant therapy with ganciclovir or valproic acid&#xD;
&#xD;
          6. Need for ongoing concomitant therapy with another antibiotic active against gram&#xD;
             negative pathogens. Concomitant therapy with Vancomycin, Daptomycin, Linezolid,&#xD;
             Clindamycin, Fidaxomicin, Nafcillin, Metronidazole, and Rifaximin will be allowed but&#xD;
             no other antibiotic agents.&#xD;
&#xD;
          7. Pregnancy or ongoing breastfeeding. Women of childbearing age must test negative on a&#xD;
             urine pregnancy test at time of screening for trial eligibility and remain either&#xD;
             abstinent or use 2 forms of highly effective contraception for the duration of the&#xD;
             IMI/REL administration during the study.&#xD;
&#xD;
          8. Inability to comply with study protocol or remain hospitalized for duration of study.&#xD;
&#xD;
          9. Life expectancy less than 72 hours in opinion of study investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher Polk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Atrium Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Polk, MD</last_name>
    <phone>704-331-9669</phone>
    <email>Christopher.Polk@atriumhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Kearney-Bryan, MS</last_name>
    <phone>704-355-0422</phone>
    <email>Jessica.KearneyBryan@atriumhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Polk, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Atrium Health</investigator_affiliation>
    <investigator_full_name>Christopher Polk</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Gram-Negative Bacterial Infections</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Relebactam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

